Cargando…
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217700/ https://www.ncbi.nlm.nih.gov/pubmed/34171494 http://dx.doi.org/10.1016/j.annonc.2021.06.018 |
| _version_ | 1783710647061577728 |
|---|---|
| author | Palich, R. Veyri, M. Vozy, A. Marot, S. Gligorov, J. Benderra, M.-A. Maingon, P. Morand-Joubert, L. Adjoutah, Z. Marcelin, A.-G. Spano, J.-P. Barrière, J. |
| author_facet | Palich, R. Veyri, M. Vozy, A. Marot, S. Gligorov, J. Benderra, M.-A. Maingon, P. Morand-Joubert, L. Adjoutah, Z. Marcelin, A.-G. Spano, J.-P. Barrière, J. |
| author_sort | Palich, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8217700 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82177002021-06-23 High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers Palich, R. Veyri, M. Vozy, A. Marot, S. Gligorov, J. Benderra, M.-A. Maingon, P. Morand-Joubert, L. Adjoutah, Z. Marcelin, A.-G. Spano, J.-P. Barrière, J. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2021-10 2021-06-22 /pmc/articles/PMC8217700/ /pubmed/34171494 http://dx.doi.org/10.1016/j.annonc.2021.06.018 Text en © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Palich, R. Veyri, M. Vozy, A. Marot, S. Gligorov, J. Benderra, M.-A. Maingon, P. Morand-Joubert, L. Adjoutah, Z. Marcelin, A.-G. Spano, J.-P. Barrière, J. High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers |
| title | High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers |
| title_full | High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers |
| title_fullStr | High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers |
| title_full_unstemmed | High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers |
| title_short | High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers |
| title_sort | high seroconversion rate but low antibody titers after two injections of bnt162b2 (pfizer-biontech) vaccine in patients treated with chemotherapy for solid cancers |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217700/ https://www.ncbi.nlm.nih.gov/pubmed/34171494 http://dx.doi.org/10.1016/j.annonc.2021.06.018 |
| work_keys_str_mv | AT palichr highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT veyrim highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT vozya highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT marots highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT gligorovj highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT benderrama highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT maingonp highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT morandjoubertl highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT adjoutahz highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT marcelinag highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT spanojp highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers AT barrierej highseroconversionratebutlowantibodytitersaftertwoinjectionsofbnt162b2pfizerbiontechvaccineinpatientstreatedwithchemotherapyforsolidcancers |